BioMarin Announces Record Revenues in First Quarter 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil falls 3% to one-week low as supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
BioMarin Pharma (BMRN) Tops Q1 EPS by 46c
April 27, 2022 4:16 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.63, $0.46 better than the analyst estimate of $0.17. Revenue for the quarter came in at $519 million versus the consensus estimate of $507.52 million.
GUIDANCE:
BioMarin Pharma sees FY2022 revenue of $2.05-2.15 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
... More